周二，BTIG将Guardant Health（纳斯达克股票代码：GH）的目标价从此前的50.00美元上调至55.00美元，同时维持对该股的买入评级。此次调整是在Guardant Health股价当天上午飙升15%之后做出的，原因是该公司宣布其Guardant Reveal MRD检测在监测环境中获得了Medicare的覆盖 ...

周五，Piper Sandler确认了对Guardant Health股票的"增持"评级，目标价保持在34.00美元。这与分析师的普遍看法一致，根据InvestingPro的数据，最近有10位分析师上调了其盈利预期，目标价范围在34美元至60美元之间。Piper Sandler的分析得到了一项最近对38位肿瘤学家关于 ...

In this article, we are going to take a look at where Guardant Health (NASDAQ:GH) stands against the other stocks. Stock gains always get people talking, and 2025 is no exception. Markets have ...

BTIG raised the firm’s price target on Guardant Health (GH) to $55 from $50 and keeps a Buy rating on the shares. The firm reiterated Guardant as a Top Pick, noting that the shares are up ...

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions ...

In this article, we are going to take a look at where Guardant Health, Inc. (NASDAQ:GH) stands against the other stocks. Wall Street’s main indices kicked off the trading week soaring on Tuesday ...

Guardant Health (GH) and Meaningful Insights Biotech Analytics, or MiBA announced a partnership aimed at optimizing the use of biomarker testing and data analytics to advance precision medicine in ...

Begin your TipRanks Premium journey today. Guardant Health (GH) Company Description: Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and ConcertAI, a leading oncology real-world evidence data and AI SaaS technology ...